Malaysian Drug Makers See Sales Passing $1 Billion By Year's End
This article was originally published in PharmAsia News
Executive Summary
Malaysia's pharmaceutical industry is expected to pass the $1 billion market by the end of this year, up 10 percent from 2008. Sales are projected at $1.1 billion, thanks primarily to the threatening H1N1 flu pandemic driving higher demand for drugs. Malaysia's drug makers also were less affected by the global economic crisis than were other industries. Jimmy Piong, president of the Malaysian Organization of Pharmaceutical Industries, said the rise in demand for H1N1 medicines offset declining sales of over-the-counter drugs at the same time sales of prescription drugs remained steady, with generics accounting for 35 percent of the Malaysian market. (Click here for more
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.